Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Gary Herman, C. Melinda Stevens, Koen Vandyck et al. · Clinical Pharmacology & Therapeutics · 2005 · 519 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

New England Journal of Medicine · 2010 · 475 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Edward S. Horton, Cynthia Clinkingbeard, Marjorie Gatlin et al. · Diabetes Care · 2000 · 244 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes

John R. Lindsay, N. A. Duffy, Aine McKillop et al. · Diabetic Medicine · 2005 · 156 citations

Medicine, Endocrinology, Pharmacology +16

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1

Brian D. Green, Nigel Irwin, Nicola Duffy et al. · European Journal of Pharmacology · 2006 · 115 citations

Medicine, Endocrinology, Pharmacology +16